Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;22(3):329-338.
doi: 10.1007/s40257-020-00584-2.

Dermatitis Herpetiformis: An Update on Diagnosis and Management

Affiliations
Review

Dermatitis Herpetiformis: An Update on Diagnosis and Management

Timo Reunala et al. Am J Clin Dermatol. 2021 May.

Abstract

Dermatitis herpetiformis (DH), presenting with an intense itch and blistering symmetrical rash, typically on the elbows, knees, and buttocks, is a cutaneous manifestation of celiac disease. Though overt gastrointestinal symptoms are rare, three-fourths of patients with DH have villous atrophy in the small bowel, and the rest have celiac-type inflammatory changes. DH affects mostly adults and slightly more males than females. The mean age at onset is about 50 years. DH diagnosis is confirmed by showing granular immunoglobulin A deposits in the papillary dermis. The DH autoantigen, transglutaminase 3, is deposited at the same site in tightly bound immune complexes. At present, the DH-to-celiac disease prevalence is 1:8. The incidence of DH is decreasing, whereas that of celiac disease is increasing, probably because of improved diagnostics. In DH, the treatment of choice for all patients is a gluten-free diet (GFD) in which uncontaminated oats are allowed. At onset, most patients need additional dapsone to rapidly control the rash and itching. Dapsone can be stopped after a mean of 2 years, and a strict lifelong GFD alone is required. Dietary adherence offers an excellent long-term prognosis for patients with DH, with a normal quality of life and all-cause mortality.

PubMed Disclaimer

Conflict of interest statement

Timo Reunala, Kaisa Hervonen, and Teea Salmi have no conflicts of interest that are directly relevant to the content of this article.

Figures

Fig. 1
Fig. 1
Dermatitis herpetiformis lesions on the a elbows and b knees: observe symmetrical distribution and erosions due to scratching. c A close-up view of a small blister. d Direct immunofluorescence finding of uninvolved skin showing pathognomonic granular immunoglobulin A deposits at the dermo-epidermal junction

References

    1. Duhring LA. Dermatitis herpetiformis. Landmark article, Aug 30, 1884. JAMA. 1983;250:212–216. doi: 10.1001/jama.1983.03340020028029. - DOI - PubMed
    1. Losowsky MS. A history of coeliac disease. Dig Dis. 2008;26:112–120. doi: 10.1159/000116768. - DOI - PubMed
    1. Marks J, Shuster S, Watson AJ. Small-bowel changes in dermatitis herpetiformis. Lancet. 1966;2:1280–1282. doi: 10.1016/S0140-6736(66)91692-8. - DOI - PubMed
    1. Fry L, Keir P, McMinn RM, Cowan JD, Hoffbrand AV. Small-intestinal structure and function and haematological changes in dermatitis herpetiformis. Lancet. 1967;2:729–733. doi: 10.1016/s0140-6736(67)91942-3. - DOI - PubMed
    1. Savilahti E, Reunala T, Mäki M. Increase of lymphocytes bearing the gamma/delta T cell receptor in the jejunum of patients with dermatitis herpetiformis. Gut. 1992;33:206–211. doi: 10.1136/gut.33.2.206. - DOI - PMC - PubMed

MeSH terms